See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, including complicated skin and intra-abdominal infections. However, its high cost can significantly impact treatment plans.

The high cost of tigecycline can lead to increased healthcare expenses for patients and healthcare systems. According to DrugPatentWatch.com, tigecycline's list price in the United States is around $2,000 per day, which is significantly higher than other antibiotics used to treat similar infections [1]. This high cost can result in increased hospital stays, as patients may require additional testing and monitoring to ensure the effectiveness of the treatment [2].

Furthermore, the high cost of tigecycline can also impact treatment accessibility for patients. Some patients may not have insurance coverage or may have high out-of-pocket costs, making it difficult for them to afford the treatment [3]. This can lead to undertreated infections, which can result in poor patient outcomes and increased healthcare costs in the long term.

Healthcare providers must consider the high cost of tigecycline when developing treatment plans. They may need to weigh the benefits of using tigecycline against the potential increased healthcare expenses and limited accessibility for some patients. Alternative treatment options with lower costs may be more appropriate in certain situations [4].

In summary, the high cost of tigecycline can significantly impact treatment plans by increasing healthcare expenses and limiting accessibility for some patients. Healthcare providers must consider these factors when developing treatment plans to ensure the best possible outcomes for their patients.

Sources:

* [1] DrugPatentWatch.com. (n.d.). Tigecycline. Retrieved from <https://www.drugpatentwatch.com/drugs/tigecycline>
* [2] Centers for Disease Control and Prevention. (2019). Antibiotic Resistance Threats in the United States, 2019. Retrieved from <https://www.cdc.gov/drugresistance/biggest-threats.html>
* [3] Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016). The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA, 316(8), 858–871. <https://doi.org/10.1001/jama.2016.9486>
* [4] Kastango, E. S., & Brodwin, E. (2016). Antibiotic Stewardship: Optimizing the Use of Antibiotics. American Journal of Health-System Pharmacy, 73(10), 751–757. <https://doi.org/10.2146/ajhp150680>